GuShiio.com ① A total of 95 investment and financing incidents occurred within domestic statistics this week, an increase of 4.40% from last week. The total disclosed financing amount was approximately 4.756 billion yuan, an increase of 82.41% from last week.
② Medical health, advanced manufacturing and other fields are among the top active; medical health disclosed the largest total financing, approximately 1.570 billion yuan.
③ Intelligent Spectrum completed strategic financing of more than 1 billion yuan, making it the largest investment event disclosed this week.
“Science and Technology Innovation Board Daily” March 8 According to data from Cailian Venture Capital, a total of 95 investment and financing incidents occurred in domestic statistics this week (3.1-3.7), an increase of 4.40% from 91 incidents last week; the total amount of financing disclosed was approximately 4.756 billion yuan, an increase of 82.41% from 2.607 billion yuan last week.
hot areas
Judging from the number of investment events, medical health, advanced manufacturing, integrated circuits, automobile travel, artificial intelligence and other fields are relatively active this week; judging from the total financing, medical health disclosed the largest total financing, about 1.570 billion yuan.wisdom spectrumCompleted more than 1 billion yuan in strategic financing involving Hangzhou Urban Investment Industrial Fund, Shangcheng Capital, etc., which was the largest investment event disclosed this week.
On the segmented track, the ones that are more popular among investors this week are medical equipment, innovative drugs, aerospace, battery materials, embodied intelligence, ceramic materials, auto parts, industrial robots, etc.
As a comparison, the performance of the secondary markets for medical devices, commercial aerospace, and humanoid robots this week is shown in the following table.
Hot investment rounds
From the perspective of investment rounds, except for equity financing, the number of Series A financing events this week remained the largest, with 26 incidents, accounting for approximately 27%; followed by the Seed Angel Round, with 21 incidents, accounting for approximately 22%. Judging from the amount of investment received in each round, the total financing disclosed in Series B was the highest, about 1.288 billion yuan; followed by strategic financing, about 1.260 billion yuan.
Active investment and financing areas
From a regional perspective, companies in Jiangsu, Guangdong, Shanghai, Beijing and other places are more popular this week, with more than 10 financing incidents; Jiangsu ranked first with 21 financing activity incidents. In terms of individual cities, Shanghai ranked first with 17 companies being invested; Beijing followed closely with 14 companies.
Active investment institutions
This week’s investors include Sequoia China, Hillhouse Ventures, Qiming Ventures, IDG Capital, Aobo Capital, Gaorong Capital, Lilly Asia Fund, Pricebook Capital, Ida Capital, Tongchuang Weiye, Huarui Investment, Qiji Chuangtan, Shuimu Tsinghua Alumni Seed Fund and other well-known investment institutions;
As well as Lenovo Venture Capital, Xiaomi Group, TCL Venture Capital, Shangqi Capital, Gree Gold Investment, Baojiehui Innovation Consumer Fund, Huahai Pharmaceutical, Hengxing New Materials, Naisi Group, Opkang, Kaizhong Shares, Shengmei Semiconductor, Shunda Health Industry Group, ZTE, Zhonghong Medical, Changchun Shengboma Biological and other industry-related investors;
It also includes Beijing State Administration, Pudong Venture Capital Group, Zhangjiang Science Investment, Chengdu Science Investment, Hangzhou City Investment, Zhuhai High-Tech Venture Capital, Nanjing City Innovation Investment Group, Taishan Industrial Development Investment Group, Guolian Group, Sichuan Province Green and Low-Carbon Industry Development Fund and other state-owned investment platforms and government guidance funds.
Some active investors this week are listed as follows:
Investment events worthy of attention
Chuji Power completed 500 million yuan Series A financing in half a year
Chuiji Power was established in 2022. Focusing on three core embodied intelligence technologies, namely the design and manufacturing of ontology hardware, cerebellar whole-body motion control based on reinforcement learning and the training strategy of embodied brain models, it focuses on size universal humanoid robots, and has derived products such as bipedal robots.
The Enterprise Innovation Evaluation Laboratory shows that Zhuji Power’s global scientific innovation capabilities in the intelligent manufacturing equipment industry are rated BB. Currently, there are more than 80 public patent applications, of which invention applications account for more than 60%, mainly focusing on robots and robot technology., humanoid robots, bipedal robots, robotic arms and other technical fields.
Recently, the company announced the completion of Series A+ financing, and has completed a total of 500 million yuan in Series A financing in half a year. Strategic industry investors include Alibaba Group, China Merchants Venture Capital, Shangqi Capital, Neilai Capital, Lenovo Venture Capital, Bianera, and Naaisi Group. Well-known financial investors include Gaojie Capital, Oasis Capital, Mingshi Venture Capital, Fengrui Capital, and Nanshanzhan New Investment.
According to the Cailian Venture Capital Connect-Implementation Data, with March 2025 as the forecast benchmark time, the financing forecast probability of Chuji Power in the next two years is 91.05%.
Venture Capital Data shows that in the past year, some of the domestic investment cases in the field of specific intelligence are as follows.
Pamu Healthcare completes nearly US$100 million in Series C financing
Founded in 2013, Pamu Medical is committed to providing breakthrough therapies in the fields of pulmonary hypertension and heart failure, with a view to delaying and improving patients ‘disease progression and enhancing patients’ life resilience. Pamu Medical’s original core technology and product,”Percutaneous Pulmonary Artery Denervation (PADN)” series of catheters and hosts, is the world’s first minimally invasive interventional therapy product for pulmonary hypertension approved by China.
The Enterprise Innovation Evaluation Laboratory shows that Pamu Medical’s global scientific and technological innovation capabilities in the biomedical engineering industry are rated as A-level. Currently, there are more than 90 public patent applications, of which invention applications account for more than 81%, and 7 PCT applications. There are patent layouts in 17 countries/regions, mainly focusing on technical fields such as radio frequency ablation, pulmonary arteries, control handles, annular rings, and adjustment devices.
Recently, the company announced that it has completed nearly US$100 million in Series C financing. This round of financing was jointly led by Qiming Venture Capital and old shareholder Lilly Asia. Existing investors Aobo Capital and Gao Rong Venture Capital made additional investments. This fundraising will be mainly used to accelerate the company’s global clinical, overseas business and strategic development planning.
According to Cailian Venture-Implementation Data, with March 2025 as the benchmark forecast time, the financing forecast probability of Pamu Medical in the next two years is 75.56%.
Venture Capital Data shows that in the past year, some investment cases in the domestic medical device field are as follows.
Yiyou Technology completes 50 million yuan in Series A financing
Yiyou Technology was established in 2018 and is committed to the research and development, production and sales of humanoid robot drive systems, with the development of integrated joint modules as its main direction. The planet, harmonic and push rod joint modules launched by the company cover the whole body joints that can be used by the upper limbs, waist and lower limbs of humanoid robots, and are adopted by many domestic head-shaped humanoid robot companies. Among them, Yiyou Technology is currently a designated supplier for mass production of intelligent robot A2 series (including A2, A2W, and A2D models).
The Enterprise Innovation Evaluation Laboratory shows that Yiyou Technology’s equity penetration and scientific innovation capabilities in the artificial intelligence industry are rated at CCC level. Yiyou Technology and its holding company currently have a total of 18 public patent applications, of which invention applications account for about 17%, mainly focusing on robots, gear motors, robot technology, rotary connections, actuators and other technical fields.
Recently, the company announced the completion of a 50 million yuan Series A financing. This round of financing is jointly led by Pudong Angel Fund, a subsidiary of Pudong Venture Capital Group, and Zhangke Yaokun Fund, a subsidiary of Zhangjiang Science Investment. TCL Venture Capital, Daosheng Capital, and Jinshi Venture Capital, a subsidiary of Tin Venture Capital, will follow the investment. The financing funds will be mainly used for core technology research and development and production capacity expansion.
According to Cailian Venture Capital Connect-Implementation Data, with March 2025 as the forecast benchmark time, Yiyou Technology’s financing forecast probability in the next two years is 85.60%.
Venture Capital Data shows that in the past year, some cases of investment in the domestic robot parts field are as follows.
List of investment and financing events this week
Venture Capital: The primary market service platform under Cailian and Science and Technology Innovation Board Daily will be listed on the Shanghai Data Exchange in April 2022. Through star mining data, primary market investment and financing data, enterprise innovation evaluation laboratory, innovative company database, self-selection of unlisted companies, early knowledge of companies to be listed, and industry investment research, it provides innovative companies and venture capital institutions with data from products to solutions.
